# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Eric Joseph maintains Enanta Pharma (NASDAQ:ENTA) with a Underweight and lowers the price target from $11 ...
HC Wainwright & Co. analyst Ed Arce reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy and maintains $27 price target.
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.45)...
HC Wainwright & Co. analyst Ed Arce maintains Enanta Pharma (NASDAQ:ENTA) with a Buy and lowers the price target from $2...
JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:ENTA) with a Market Outperform and lowers the price targ...
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.47) per share which missed the analyst consensus estimate of $(1.3...
JP Morgan analyst Eric Joseph maintains Enanta Pharma (NASDAQ:ENTA) with a Underweight and lowers the price target from $12 ...
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.58) per share which missed the analyst consensus estimate of $(1.2...